Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2007 Jul;51(7):2591-3.
doi: 10.1128/AAC.01562-06. Epub 2007 Apr 9.

In vitro activities of CG400549, a novel FabI inhibitor, against recently isolated clinical staphylococcal strains in Korea

Jong Hwa Yum  1 , Chang Ki Kim, Dongeun Yong, Kyungwon Lee, Yunsop Chong, Cheol Min Kim, Jeong Mi Kim, Seonggu Ro, Joong Myung Cho
Affiliations
Comparative Study

In vitro activities of CG400549, a novel FabI inhibitor, against recently isolated clinical staphylococcal strains in Korea

Jong Hwa Yum et al. Antimicrob Agents Chemother. 2007 Jul.

Abstract

The in vitro activities of CG400549, a novel FabI inhibitor, were compared to those of linezolid and commonly used antimicrobials against recent bacterial isolates. CG400549 had an MIC(90) of 0.5 microg/ml for Staphylococcus aureus strains and was more potent than either linezolid or vancomycin.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Structure of CG400549, a FabI inhibitor.
See this image and copyright information in PMC

References

    1. Bannerman, T. L. 2003. Staphylococcus, Micrococcus, and other catalase-positive cocci that grow aerobically, pp. 384-404. In P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology, 8th ed. American Society for Microbiology, Washington, DC.
    1. Clinical and Laboratory Standards Institute. 2005. Performance standards for antimicrobial susceptibility testing; 15th informational supplement (aerobic dilution). CLSI/NCCLS M100-S15. Clinical and Laboratory Standards Institute, Wayne, PA.
    1. Diekema, D. J., and R. N. Jones. 2001. Oxazolidinone antibiotics. Lancet 3581975-1983. - PubMed
    1. Kim, C. M., J. Kwak, C. Lee, H. Park, S. Kang, J. Kim, Y. Song, S. Ro, T. Lee, and J. Cho. 2005. CG400549, a novel FabI inhibitor with potent in vivo activity, abstr. F-1880, p. 218. Abstr. 45th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
    1. Kitagawa, H., K. Kumura, S. Takahta, M. Iida, and K. Atsumi. 2006. 4-Pyridone derivatives as new inhibitors of bacterial enoyl-ACP reductase FabI. Bioorg. Med. Chem. 151106-1116. - PubMed

Publication types

MeSH terms

LinkOut - more resources